Amphastar Pharma Stock Price, News & Analysis

Amphastar Pharmaceuticals (NASDAQ:AMPH) has received FDA approval for its Vasopressin injection (20 Units/mL, 1mL Single Dose Vial), which is used to increase blood pressure in adults with vasodilatory shock. This approval follows a tentative approval received in December 2021. The total U.S. market for vasopressin injection was approximately $714 million for the 12 months ending March 31, 2022. Amphastar plans to launch the product shortly. The company has several additional products in its pipeline with a combined market potential of approximately $25.3 billion.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will present at the Jefferies Healthcare Conference on June 8, 2022, at 8:00 am EST. The presentation will be led by Bill Peters, Executive VP and CFO, and Dan Dischner, VP of Corporate Communications. Investors can access the live webcast on Amphastar's website, which will be available for 90 days post-event. Amphastar specializes in developing and marketing injectable and inhalation products, primarily for urgent care settings.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has received FDA approval for its Regadenoson injection, a critical radiopharmaceutical for myocardial perfusion imaging, particularly for patients unable to exercise adequately. This product positions Amphastar to compete in a market previously dominated by Astellas Pharma's Lexiscan, which had $650 million in U.S. sales over the past year. The commercialization timing is subject to a confidential settlement with Astellas. Amphastar's portfolio includes three ANDAs targeting a $3.3 billion market, three biosimilars worth $13 billion, and eight generics amounting to $9 billion.

Amphastar Pharmaceuticals reported net revenues of $120.4 million for the first quarter of 2022, a 17% increase from $103 million during the same period in 2021. GAAP net income was $24.3 million, or $0.47 per share, significantly up from $5 million last year. Key product sales included a 34% rise in Primatene Mist and a 38% increase in Glucagon. Although API sales decreased by 26%, the overall gross profit rose by 24% to $55.8 million. The board also authorized a $25 million increase to the share buyback program.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will announce its first quarter 2022 results on May 9, 2022, after market closure. A conference call to discuss the results is scheduled for 2:00 p.m. Pacific Time. Interested participants can join by dialing (877) 407-0989 (toll-free) or (201) 389-0921 (international) five minutes prior to the call. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital use. For more information, visit www.amphastar.com.

Amphastar Pharmaceuticals has received FDA approval for its Ganirelix Acetate Injection, a 250mg/0.5mL prefilled syringe, indicated for controlling premature LH surges in women undergoing ovarian hyperstimulation. This marks the company's fourth injectable peptide product approval, with plans for market launch in Q2 2022. The U.S. market for Ganirelix is valued at approximately $89 million as of the end of 2021. Amphastar's pipeline includes four ANDAs targeting a market size of $3.9 billion and several biosimilars and generics, enhancing its market position.

Amphastar Pharmaceuticals (NASDAQ:AMPH) will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022. This event, featuring key executives including Bill Peters and Dan Dischner, is scheduled for 12:45 pm EST. The presentation will be accessible through Amphastar's website and available for 90 days post-event. Amphastar focuses on developing and marketing generic and proprietary injectable products. More details can be found on their website at ir.amphastar.com.

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported net revenues of $120.9 million for Q4 2021, a 26% increase year-over-year. GAAP net income stood at $19.8 million or $0.39 per share. For the fiscal year, revenues totaled $437.8 million, up 25%, with GAAP net income of $62.1 million, reflecting the company's strong performance in higher-margin products like Primatene Mist and epinephrine. The company anticipates further growth with multiple pipeline milestones set for 2022.

Amphastar Pharmaceuticals (NASDAQ:AMPH) will release its fourth-quarter 2021 results on March 10, 2022, after market close. A conference call discussing the financial results is scheduled for 2:00 p.m. Pacific Time. The company specializes in developing injectable, inhalation, and intranasal products, mainly used in hospital settings. Amphastar cautions that its forward-looking statements involve uncertainties and risks, and actual results may differ from expectations. Investors can access details on the company's website.